[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100645214":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":10,"centralContacts":15,"locations":25,"responsibleParty":41,"collaborators":10,"id":45,"slug":46,"hasResults":47,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":51,"eligibilityCriteria":52,"healthyVolunteers":47,"sex":53,"minAge":54,"maxAge":10,"enrollmentInfo":55,"targetDuration":10,"studyType":58,"phases":10,"briefSummary":59,"conditions":60,"keywords":10,"overallStatus":62,"whyStopped":10,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":64,"startDateStruct":67,"completionDateStruct":69,"leadSponsor":71,"locationsCount":72},{"fullName":5,"class":6},"Fondazione Policlinico Universitario Agostino Gemelli IRCCS","OTHER",[8,12],{"label":9,"type":10,"description":11,"interventionNames":10},"Dexmedetomidine during HFNC",null,"The procedure performed as part of routine clinical practice involves the administration of high-flow nasal oxygen therapy (HFNC), with an initial flow set at 60 L\u002Fmin, potentially reduced to the maximum tolerated flow in case of discomfort. FiO₂ is titrated to maintain the target SpO₂ of 92-96%. Humidification chamber is heated at 37°C or 34°C according to patient's comfort. During the procedure, patients receive sedative-analgesic treatment with dexmedetomidine as a clinical indication decided by the attending physician.",{"label":13,"type":10,"description":14,"interventionNames":10},"Remifentanil during HFNC","The procedure performed as part of routine clinical practice involves the administration of high-flow nasal oxygen therapy (HFNC), with an initial flow set at 60 L\u002Fmin, potentially reduced to the maximum tolerated flow in case of discomfort. FiO₂ is titrated to maintain the target SpO₂ of 92-96%. Humidification chamber is heated at 37°C or 34°C according to patient's comfort. During the procedure, patients receive sedative-analgesic treatment with remifentanil as a clinical indication decided by the attending physician.",[16,21],{"name":17,"role":18,"phone":19,"phoneExt":10,"email":20},"Domenico Luca Grieco, MD","CONTACT","+393397681623","dlgrieco@outlook.it",{"name":22,"role":18,"phone":23,"phoneExt":10,"email":24},"Gaia Tempo, MD","+393450947767","gaia.tempo9@gmail.com",[26],{"facility":27,"status":10,"city":28,"state":29,"zip":30,"country":31,"countryCode":32,"cosmosGeoPoint":33,"geoPoint":38,"contacts":39},"Fondazione Policlinico Universitario A.Gemelli IRCCS","Roma","RM","00168","Italy","IT",{"type":34,"coordinates":35},"Point",[36,37],11.10642,44.99364,{"lat":37,"lon":36},[40],{"name":17,"role":18,"phone":19,"phoneExt":10,"email":20},{"type":42,"investigatorFullName":43,"investigatorTitle":44,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"PRINCIPAL_INVESTIGATOR","GRIECO DOMENICO LUCA","Medical Doctor, Principal Investigator","100645214","optimization-of-respiratory-effort-with-titrated-sedation-in-ahrf-100645214",false,"NCT07679932","Optimization of Respiratory Effort With Titrated Sedation in AHRF","Optimization of Respiratory Effort With Titrated Sedation in Patients With Acute Hypoxemic Respiratory Failure - The OPTIREST Study","OPTIREST","Inclusion Criteria:\n\n* Age ≥18 years\n* PaO2\u002FFiO2 ratio ≤ 200;\n* PaCO2 \\\u003C 45 mmHg;\n* At least one symptom prompting the use of sedative-analgesic drugs according to the prescription of the attending physician: dyspnea and\u002For discomfort equal of greater than 4\u002F10 (Visual Analog Scale - VAS), respiratory rate equal or greater than 25 breaths per minute, PaCO2\\\u003C35 mmHg, pain (Numeric Rating Scale ≥ 4 or Behavioral Pain Scale - Non-Intubated ≥ 4);\n* Informed consent signature.\n\nExclusion Criteria:\n\n* Pregnancy;\n* Exacerbation of asthma or chronic obstructive pulmonary disease;\n* Chronic lung disease, requiring oxygen therapy at home;\n* Cardiogenic pulmonary oedema;\n* Hemodynamic instability (systolic blood pressure \\\u003C90 mmHg or mean arterial pressure \\\u003C65 mmHg) and\u002For lactic acidosis (lactate \\>5 mmol\u002FL) and\u002For clinically diagnosed shock;\n* Metabolic acidosis (pH \\\u003C7.30 with normal or hypocarbia);\n* Glasgow Coma Scale \\\u003C13;\n* Contraindications to esophageal balloon and\u002For EIT placement.","ALL","18 Years",{"count":56,"type":57},40,"ESTIMATED","OBSERVATIONAL","Prospective, observational, monocentric study to assess the physiological effects of dexmedetomidine and remifentanil in spontaneously breathing patients with acute hypoxemic respiratory failure receiving high-flow nasal oxygen.",[61],"AHRF","NOT_YET_RECRUITING","2026-06-25",{"date":65,"type":66},"2026-07-01","ACTUAL",{"date":68,"type":57},"2026-07",{"date":70,"type":57},"2028-07",{"name":5,"class":6},1]